Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Fig. 1

Overall survival: 5-year pooled data. OS analysis of 5-year pooled data from the COMFORT-I and -II trials. Data are presented a for the ITT population, b corrected for crossover with the RPSFT model, c censored at crossover, and d stratified by IPSS risk status. Originally presented at the American Society of Hematology 58th Annual Meeting [13]. HR, hazard ratio; int-2, intermediate-2; IPSS, International Prognostic Scoring System; ITT, intent-to-treat; NE, not evaluable; OS, overall survival; RPSFT, rank-preserving structural failure time

Back to article page